Truist raised the firm’s price target on Insmed (INSM) to $139 from $126 and keeps a Buy rating on the shares. The firm is positive on the stock and updating its model following approval of BRINSUPRI – brensocatib – with broad label that could support a multi-billion dollar opportunity, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on INSM:
- H.C. Wainwright doubles Insmed target to $240 on ‘pipeline-in-a-pill’ potential
- C3 AI downgraded, Capri upgraded: Wall Street’s top analyst calls
- Insmed price target raised to $140 from $133 at UBS
- Insmed downgraded to Equal Weight from Overweight at Morgan Stanley
- Insmed’s Brensocatib Approval Boosts Market Potential and Stock Valuation